Please try another search
For the fiscal year ended 31 December 2019, Kiwa Bio-Tech Products Group Corporation revenues increased 31% to $40.1M. Net loss totaled $6.6M vs. income of $344K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Interest expense increase from $635K to $3.9M (expense), Change in fair value of derivative liab. decrease of 58% to $102K (income).
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Revenue | 8.64 | 10.99 | 10.92 | 9.54 |
Gross Profit | 1.42 | 2.58 | 0.72 | 2.18 |
Operating Income | -3.47 | 1.85 | -0.74 | 1.18 |
Net Income | -5.09 | 0.31 | -2.25 | 0.39 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Assets | 24.07 | 33.15 | 32.24 | 35.87 |
Total Liabilities | 14.38 | 19.56 | 19.14 | 20.62 |
Total Equity | 9.69 | 13.59 | 13.1 | 15.25 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 0.18 | 0.31 | -1.53 | -0.54 |
Cash From Investing Activities | -2.07 | -0 | -0.04 | 0 |
Cash From Financing Activities | 1.48 | 1.24 | 0.99 | 0.94 |
Net Change in Cash | 0 | 2.01 | 0 | 0.35 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review